Athersys Future Hinges on Stem Cell Stroke Study Results – TheStreet.com
TheStreet.com |
Athersys Future Hinges on Stem Cell Stroke Study Results
TheStreet.com The company’s stock price plunged last April when MultiStem, the stem cell therapy, failed to benefit ulcerative colitis patients. The MultiStem stroke study is Athersys’ best and perhaps last chance for redemption. Athersys shares were trading around … Great Timing For Athersys, Other Stem Cell Companies Amidst Improving …MarketWatch |
The Australian Financial Review |
Celgene buys into Mesoblast’s stem cell pipeline in regenerative med pact
FierceBiotech Celgene has stepped up with a deal to buy a $45 million chunk of Mesoblast’s stock at a premium price in exchange for a front row seat on the Australian biotech’s stem cell pipeline and a preferred spot at the bargaining table if it follows up with a … Stem cell pioneer lures big pharmaThe Australian Financial Review Shares in this Australian stem cell company are going nuts on an investment …Business Insider Australia Mesoblast Shoots To A 4-Year High On News Of Celgene Corporation Buying …Bidness ETC Sydney Morning Herald –Bloomberg –GlobeNewswire (press release) all 37 news articles » |
The Australian Financial Review |
Celgene buys into Mesoblast’s stem cell pipeline in regenerative med pact
FierceBiotech Celgene has stepped up with a deal to buy a $45 million chunk of Mesoblast’s stock at a premium price in exchange for a front row seat on the Australian biotech’s stem cell pipeline and a preferred spot at the bargaining table if it follows up with a … Stem cell pioneer lures big pharmaThe Australian Financial Review Shares in this Australian stem cell company are going nuts on an investment …Business Insider Australia Mesoblast Shoots To A 4-Year High On News Of Celgene Corporation Buying …Bidness ETC Sydney Morning Herald –Bloomberg –GlobeNewswire (press release) all 37 news articles » |